FR16C0004I2 - Composes cepheme - Google Patents

Composes cepheme

Info

Publication number
FR16C0004I2
FR16C0004I2 FR16C0004C FR16C0004C FR16C0004I2 FR 16C0004 I2 FR16C0004 I2 FR 16C0004I2 FR 16C0004 C FR16C0004 C FR 16C0004C FR 16C0004 C FR16C0004 C FR 16C0004C FR 16C0004 I2 FR16C0004 I2 FR 16C0004I2
Authority
FR
France
Prior art keywords
cephem compounds
cephem
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR16C0004C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2002952355A external-priority patent/AU2002952355A0/en
Priority claimed from AU2003904813A external-priority patent/AU2003904813A0/en
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of FR16C0004I1 publication Critical patent/FR16C0004I1/fr
Application granted granted Critical
Publication of FR16C0004I2 publication Critical patent/FR16C0004I2/fr
Active legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D501/00Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D501/00Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/207-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • C07D501/247-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
    • C07D501/38Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof
    • C07D501/46Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof with the 7-amino radical acylated by carboxylic acids containing hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FR16C0004C 2002-10-30 2016-02-03 Composes cepheme Active FR16C0004I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2002952355A AU2002952355A0 (en) 2002-10-30 2002-10-30 Cephem compounds
AU2003904813A AU2003904813A0 (en) 2003-09-04 Cephem Compounds
PCT/JP2003/013684 WO2004039814A1 (en) 2002-10-30 2003-10-27 Cephem compounds

Publications (2)

Publication Number Publication Date
FR16C0004I1 FR16C0004I1 (fr) 2016-03-25
FR16C0004I2 true FR16C0004I2 (fr) 2017-01-06

Family

ID=32231625

Family Applications (1)

Application Number Title Priority Date Filing Date
FR16C0004C Active FR16C0004I2 (fr) 2002-10-30 2016-02-03 Composes cepheme

Country Status (19)

Country Link
US (2) US7129232B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP1556389B9 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP4448821B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR101023035B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (1) AR041729A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE368042T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE (1) BE2016C002I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BRPI0315188B8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2504730C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE60315178T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK1556389T6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2290498T7 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR16C0004I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUS1600008I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LU (1) LU92943I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL300793I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT1556389E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TWI319403B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2004039814A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE318269T1 (de) * 2001-05-01 2006-03-15 Astellas Pharma Inc Cephem-verbindungen
CA2504730C (en) * 2002-10-30 2011-04-12 Astellas Pharma Inc. Cephem compounds
AU2003902380A0 (en) * 2003-05-16 2003-06-05 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
ES2340928T3 (es) 2003-09-18 2010-06-11 Astellas Pharma Inc. Compuestos de cefem.
EP2308562B1 (en) * 2003-12-25 2015-02-25 Ono Pharmaceutical Co., Ltd. Azetidine ring compounds and drugs comprising the same
EP1994035A1 (en) * 2006-03-16 2008-11-26 Astellas Pharma Inc. Cephem compounds and use as antimicrobial agents
ITFE20060029A1 (it) * 2006-10-17 2008-04-18 Gruppo Kemon Spa Intermedi eterociclici primari per la colorazione ossidativa dei capelli a struttura pirazolica
CA2935651A1 (en) 2007-10-09 2009-04-16 Gladius Pharmaceuticals Corporation Broad spectrum beta-lactamase inhibitors
CN108329246B (zh) 2011-05-13 2021-02-26 阵列生物制药公司 作为trka激酶抑制剂的吡咯烷基脲和吡咯烷基硫脲化合物
EA028342B1 (ru) 2011-09-09 2017-11-30 Мерк Шарп И Доум Корп. Способы лечения пневмонии
EP2628730B1 (en) * 2012-02-16 2017-12-06 Noxell Corporation Telescoping synthesis of 5-amino-4-nitroso-1-alkyl-1h-pyrazole salts
US8809314B1 (en) 2012-09-07 2014-08-19 Cubist Pharmacueticals, Inc. Cephalosporin compound
MX2015004039A (es) 2012-09-27 2015-10-29 Cubist Pharm Inc Composiciones de antibiotico de tazobactam arginina.
US8476425B1 (en) 2012-09-27 2013-07-02 Cubist Pharmaceuticals, Inc. Tazobactam arginine compositions
US9006421B2 (en) 2013-03-14 2015-04-14 Cubist Pharmaceuticals, Inc. Cephalosporin compositions and methods of manufacture
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
US20140274991A1 (en) 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Ceftolozane pharmaceutical compositions
NZ700372A (en) 2013-03-15 2016-01-29 Merck Sharp & Dohme Ceftolozane antibiotic compositions
US10376496B2 (en) 2013-09-09 2019-08-13 Merck, Sharp & Dohme Corp. Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
US20160228448A1 (en) * 2013-09-27 2016-08-11 Merck Sharp & Dohme Corp. Solid Forms of Ceftolozane
US20150094293A1 (en) * 2013-09-27 2015-04-02 Calixa Therapeutics, Inc. Solid forms of ceftolozane
WO2015051101A1 (en) 2013-10-02 2015-04-09 Cubist Pharmaceuticals, Inc. B-lactamase inhibitor picoline salt
MY191956A (en) 2014-05-15 2022-07-20 Array Biopharma Inc 1-((3s,4r)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1h-pyrazol-5-yl)urea as a trka kinase inhibitor
US10221196B2 (en) 2014-08-15 2019-03-05 Merck Sharp & Dohme Corp. Intermediates in the synthesis of cephalosporin compounds
WO2016025839A1 (en) 2014-08-15 2016-02-18 Merck Sharp & Dohme Corp. Synthesis of cephalosporin compounds
US10000510B2 (en) 2014-08-18 2018-06-19 Merck Sharp & Dohme Corp. Salt forms of ceftolozane
US10035774B2 (en) 2014-12-18 2018-07-31 Merck Sharp & Dohme Corp. Pyrazolyl carboxylic acid and pyrazolyl urea derivative compounds
WO2016100897A1 (en) * 2014-12-18 2016-06-23 Merck Sharp & Dohme Corp. Thiadiazolyl-oximinoacetic acid derivative compounds
US20160176897A1 (en) 2014-12-23 2016-06-23 Merck Sharp & Dohme Corp. 7-aminocephem derivative compounds
US10214543B2 (en) 2014-12-30 2019-02-26 Merck Sharp & Dohme Corp. Synthesis of cephalosporin compounds
ES2729026T3 (es) 2015-06-29 2019-10-29 Sandoz Ag Procedimiento para la preparación de derivados de carbamoilamino pirazol
CA2991521A1 (en) 2015-09-08 2017-03-16 Sandoz Ag Process for preparing ceftolozane from 7-aminocephalosporanic acid (7-aca)
EA039648B1 (ru) 2015-12-10 2022-02-21 НАЕДЖА-АрДжиЭм ФАРМАСЬЮТИКАЛЗ ЮЭлСи Соединения цефема, их получение и применение
ES2973874T3 (es) 2016-06-06 2024-06-24 Merck Sharp & Dohme Llc Formas sólidas de ceftolozano y procesos para su preparación
CN107586305A (zh) * 2017-06-23 2018-01-16 浙江惠迪森药业有限公司 一种β‑内酰胺类化合物羧基及羟基保护基脱除方法
WO2019145784A2 (en) * 2018-01-26 2019-08-01 Legochem Biosciences, Inc. Combination therapies for multi-drug resistant pathogens
CN109369535A (zh) * 2018-11-07 2019-02-22 浙江东邦药业有限公司 一种氨基甲酰氨基吡唑衍生化合物的制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR78245B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1980-09-12 1984-09-26 Ciba Geigy Ag
US5194432A (en) * 1985-11-22 1993-03-16 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
CA1293719C (en) * 1986-09-22 1991-12-31 Takao Takaya Cephem compounds and processes for preparation thereof
US5210080A (en) * 1987-09-07 1993-05-11 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
US5663163A (en) * 1987-09-07 1997-09-02 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds and processes for preparation thereof
IE63094B1 (en) * 1987-09-14 1995-03-22 Fujisawa Pharmaceutical Co Cephem compound and a process for preparation thereof
US5173485A (en) * 1988-03-09 1992-12-22 Fujisawa Pharmaceutical Company, Ltd. Cephem compounds
GB8905301D0 (en) * 1989-03-08 1989-04-19 Fujisawa Pharmaceutical Co New cephem compound and a process for preparation thereof
US5215982A (en) * 1989-11-10 1993-06-01 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
KR910015587A (ko) * 1990-02-27 1991-09-30 후지사와 토모키치로 세펨 화합물
GB9023479D0 (en) * 1990-10-29 1990-12-12 Fujisawa Pharmaceutical Co New cephem compounds and processes for preparation thereof
JPH09110877A (ja) 1995-10-17 1997-04-28 Katayama Seiyakushiyo:Kk セフェム化合物、その製造法及びそれを含有する抗菌剤
AUPN955596A0 (en) 1996-04-30 1996-05-23 Fujisawa Pharmaceutical Co., Ltd. New compound
TW526202B (en) * 1998-11-27 2003-04-01 Shionogi & Amp Co Broad spectrum cephem having benzo[4,5-b]pyridium methyl group of antibiotic activity
ATE318269T1 (de) * 2001-05-01 2006-03-15 Astellas Pharma Inc Cephem-verbindungen
CA2504730C (en) * 2002-10-30 2011-04-12 Astellas Pharma Inc. Cephem compounds
AU2003902380A0 (en) * 2003-05-16 2003-06-05 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
ES2340928T3 (es) * 2003-09-18 2010-06-11 Astellas Pharma Inc. Compuestos de cefem.

Also Published As

Publication number Publication date
CA2504730C (en) 2011-04-12
DE60315178D1 (de) 2007-09-06
DE60315178T3 (de) 2015-06-18
HUS1600008I1 (hu) 2016-03-29
DK1556389T3 (da) 2007-11-26
PT1556389E (pt) 2007-11-08
EP1556389A1 (en) 2005-07-27
US7129232B2 (en) 2006-10-31
JP2006506459A (ja) 2006-02-23
AR041729A1 (es) 2005-05-26
DE60315178T2 (de) 2008-04-30
NL300793I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2016-03-15
US20070037786A1 (en) 2007-02-15
DK1556389T6 (da) 2015-05-11
ES2290498T7 (es) 2015-07-10
BRPI0315188B1 (pt) 2017-04-25
TWI319403B (en) 2010-01-11
KR101023035B1 (ko) 2011-03-24
US20040132994A1 (en) 2004-07-08
CA2504730A1 (en) 2004-05-13
FR16C0004I1 (fr) 2016-03-25
ATE368042T1 (de) 2007-08-15
EP1556389B1 (en) 2007-07-25
BRPI0315188B8 (pt) 2021-05-25
BE2016C002I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2023-03-07
NL300793I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2016-03-15
JP4448821B2 (ja) 2010-04-14
WO2004039814A1 (en) 2004-05-13
EP1556389B9 (en) 2015-09-09
BR0315188A (pt) 2005-09-06
KR20050084897A (ko) 2005-08-29
TW200410977A (en) 2004-07-01
LU92943I2 (fr) 2016-03-14
EP1556389B3 (en) 2015-04-01
ES2290498T3 (es) 2008-02-16
HK1086566A1 (zh) 2006-09-22

Similar Documents

Publication Publication Date Title
FR16C0004I2 (fr) Composes cepheme
MA27105A1 (fr) Nouveaux composes
EP1699760A4 (en) ANTIHYPERCHOLESTERINAMIC COMPOUNDS
DE60328309D1 (de) Ssigkeiten
DE60330526D1 (de) Tonerteilchenherstellungsvervahren
DE60312848D1 (de) Verbindungsanschluss
NO20044046L (no) Substituerte hydroksyetylaminer
IS7381A (is) Efnasambönd
DE60326590D1 (de) Tend lamotrigin
ATE463248T1 (de) Cephem-verbindungen
IS7414A (is) Oxó-azabísýklísk efnasambönd
NO20045659L (no) Forbindelser
NO20031114L (no) Signallys
ATE318269T1 (de) Cephem-verbindungen
ATE496887T1 (de) Substituierte 5-aminomethyl-1h-pyrrol-2-carbons ureamide
DE60302827D1 (de) Hochgeschwindigheitfräsmaschine
DE60332551D1 (de) Ic-tag
DE60323585D1 (de) Seilzugeinstellseinrichtung
EP1499310A4 (en) MONOCITRATE MONOHYDRATE OF CARVEDILOL
EP1658301A4 (en) N-DESMETHYL N-SUBSTITUTED 11-DESOXYERYTHROMYCIN COMPOUNDS
FR2839740B3 (fr) Bourrelet perfectionne
DE60335246D1 (de) Gewebsreparaturmatrix
DE60233684D1 (de) Dampfphasenepitaxiebauelement
ATE396192T1 (de) N-sulfonylaminothiazole
DE60324662D1 (de) Navigationsumschalteinrichtung